Detailed price information for Novo Nordisk A/S ADR (NVO-N) from The Globe and Mail including charting and trades.

In one research, over four months participants on the Allurion Program showed a 14% drop in overall weight and a 5.6% gain in lean body mass. Another trial revealed a 15.7% weight decrease devoid of ...

Investing.com -- Shares of Allurion Technologies (NYSE: ALUR) skyrocketed by 350% following the company's announcement of its plans to initiate a clinical study aimed at optimizing muscle mass during ...

This is where Allurion’s unique approach comes into play. Previous studies have demonstrated that patients using the Allurion Gastric Balloon in combination with the Allurion Virtual Care Suite ...

Allurion stock soars on weight-loss therapy update. Stardust Power breaks ground on Oklahoma lithium refinery. OpenAI ...

The Allurion Program is a weight-loss platform that combines the Allurion Gastric Balloon, the world’s first and only swallowable, procedure-less TM gastric balloon for weight loss, the Allurion ...

NATICK, Mass. - Allurion Technologies, Inc. (NYSE: ALUR), known for its efforts in combating obesity and maintaining ...

Allurion Technologies, Inc. (ALUR) a Massachusetts-based medical device company Tuesday announced the issuance of a new U.S. patent ...

NATICK, Mass. - Allurion Technologies, Inc. (NYSE: ALUR), a company focused on obesity treatment solutions, has expanded its ...

Allurion Technologies, Inc. ("Allurion" or the "Company") (NYSE: ALUR), a company dedicated to ending obesity, today announced that it has received an Issue Notification from the U.S. Patent and ...

Allurion Technologies shares rose after agreeing to a private placement with expected gross proceeds of $2.5 million that will extend its runway through early 2026. The stock was up 13% to $3.37 ...

The Allurion Program is a weight-loss platform that combines the Allurion Gastric Balloon, the world’s first and only swallowable, procedure-lessTM gastric balloon for weight loss, the ...